OUR INVESTORS

Argobio, a start-up studio based in Paris, France, specializes in transforming cutting-edge innovations into groundbreaking biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and development.

Northern Gritstone is a groundbreaking investment company, which is dedicated to supporting the commercialisation of academic spin-outs and IP-rich businesses based in the North of England. Launched in July 2021 by the Universities of Leeds, Manchester and Sheffield, it was founded with the philosophy of Profit with Purpose, combining strong returns for investors with wider positive, societal and economic impact, including supporting Levelling Up and high-skilled job creation in the North of England. The company is deploying more than £300m of capital, having secured commitments from a broad and diverse base of investors including British Patient Capital, Greater Manchester Pension Fund, West Yorkshire Pension Fund, M&G and Columbia Threadneedle, among others. It is dedicated to financing companies in some of the UK’s fastest growing sectors such as advanced materials, energy, health technology and cognitive computation and has already made 11 investments in some of the UK’s most exciting future science and technology-enabled businesses.